Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Assertio Therapeutics stock

Learn how to easily invest in Assertio Therapeutics stock.

Assertio Therapeutics is a drug manufacturers-specialty & generic business based in the US. Assertio Therapeutics shares (ASRT) are listed on the NASDAQ and all prices are listed in US Dollars. Assertio Therapeutics employs 19 staff and has a trailing 12-month revenue of around $139.2 million.

How to buy Assertio Therapeutics stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – ASRT. It's that simple.

Best for beginners

Finder Award


  • Trade stocks and ETFs for $0 and no annual fee
  • Minimum deposit of $10 required
  • Get $10 when you sign up and deposit $100

Promoted for easy user experience


  • Commission-free trading
  • Commission-free crypto
  • No minimum account balance

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Assertio Therapeutics stock price (NASDAQ: ASRT)

Use our graph to track the performance of ASRT stocks over time.

Assertio Therapeutics shares at a glance

Information last updated 2023-01-19.
Latest market close$4.29
52-week range$1.86 - $4.44
50-day moving average $3.46
200-day moving average $2.97
Wall St. target price$7.19
PE ratio 6.5556
Dividend yield $0 (0%)
Earnings per share (TTM) $0.54

Buy Assertio Therapeutics stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
Stocks, Options, ETFs, Cryptocurrency
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

*Signup bonus information updated weekly.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Assertio Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Assertio Therapeutics price performance over time

Historical closes compared with the close of $4.29 from 2023-01-25

1 week (2023-01-19) 15.01%
1 month (2022-12-23) 5.15%
3 months (2022-10-26) 75.10%
6 months (2022-07-26) 22.57%
1 year (2022-01-26) 88.16%
2 years (2021-01-26) 518.96%
3 years (2020-01-24) 283.04%
5 years (2018-01-26) 7.81

Is Assertio Therapeutics stock undervalued or overvalued?

Valuing Assertio Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Assertio Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Assertio Therapeutics's P/E ratio

Assertio Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 7x. In other words, Assertio Therapeutics shares trade at around 7x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Assertio Therapeutics's PEG ratio

Assertio Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.6155. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Assertio Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Assertio Therapeutics's EBITDA

Assertio Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $86.8 million.

The EBITDA is a measure of a Assertio Therapeutics's overall financial performance and is widely used to measure a its profitability.

Assertio Therapeutics financials

Revenue TTM $139.2 million
Operating margin TTM 39.08%
Gross profit TTM $95.8 million
Return on assets TTM 10.92%
Return on equity TTM 22.16%
Profit margin 18.45%
Book value $2.80
Market capitalisation $171 million

TTM: trailing 12 months

Assertio Therapeutics share dividends

We're not expecting Assertio Therapeutics to pay a dividend over the next 12 months.

Have Assertio Therapeutics's shares ever split?

Assertio Therapeutics's shares were split on a 1:4 basis on 17 May 2021. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Assertio Therapeutics shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Assertio Therapeutics shares which in turn could have impacted Assertio Therapeutics's share price.

Assertio Therapeutics share price volatility

Over the last 12 months, Assertio Therapeutics's shares have ranged in value from as little as $1.86 up to $4.44. A popular way to gauge a stock's volatility is its "beta".

ASRT.US volatility(beta: 1.51)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Assertio Therapeutics's is 1.5051. This would suggest that Assertio Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Assertio Therapeutics overview

Assertio Holdings, Inc. , a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020.

Frequently asked questions

What percentage of Assertio Therapeutics is owned by insiders or institutions?
Currently 1.78% of Assertio Therapeutics shares are held by insiders and 35.999% by institutions.
How many people work for Assertio Therapeutics?
Latest data suggests 19 work at Assertio Therapeutics.
When does the fiscal year end for Assertio Therapeutics?
Assertio Therapeutics's fiscal year ends in December.
Where is Assertio Therapeutics based?
Assertio Therapeutics's address is: 100 South Saunders Road, Lake Forest, IL, United States, 60045
What is Assertio Therapeutics's ISIN number?
Assertio Therapeutics's international securities identification number is: US04546C2052
What is Assertio Therapeutics's CUSIP number?
Assertio Therapeutics's Committee on Uniform Securities Identification Procedures number is: 04545L107

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site